Ovarian Reserve in Intensive Care Patients

Evaluation of Ovarian Reserve in Critically Ill Patients Followed in the Intensive Care Unit

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06999291

Enrollment

Registered

2025-05-31

Start date

2025-06-15

Completion date

2025-11-15

Last updated

2025-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-Mullerian Hormone Deficiency

Brief summary

Gastrointestinal, pulmonary, nephrological, cardiac, neurologic and psychological effects in critically ill patients followed in the intensive care unit have been shown in the literature. However, the effects on ovarian reserve in these patients have not been sufficiently investigated and studies investigating this issue are limited in the literature. The synthesis, release frequency and amplitude of reproductive hormones change under stress. In addition, changes in ovarian homeostasis affect ovarian reserve. The aim of this study was to evaluate ovarian reserve in critically ill patients followed up in the intensive care unit.

Interventions

BEHAVIORALGlaskow coma scala, The Acute Physiology and Chronic Health Evaluation System- APACHE, Injury Severity Score- ISS)

The uterus, endometrium and ovarian characteristics, endometrial thickness, ovarian follicle number and ovarian volume parameters, hormone panel (FSH, LH, E2, AMH), cortisol, prolactin and thyroid function tests routinely examined for ovarian reserve will be evaluated in the study.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 35 Years

Healthy volunteers

Inclusion criteria

* 18-35 years of age * Female patients followed in the intensive care unit for more than 24 hours for internal or surgical reasons, * Women whose ovarian reserve is being evaluated,

Exclusion criteria

* Previous ovarian surgery, endometriosis, endometrioma, * History of chemotherapy, radiotherapy, * Ovarian cyst, malignancy and other ovarian pathologies, * Women with single ovary, * Women receiving hormone therapy, * Polycystic ovary syndrome, * Surgical intervention within the last 6 months, * History of drug, alcohol, substance use, * Women in pregnancy, puerperium, lactation, * History of vaccination within the last 6 months

Design outcomes

Primary

Measure	Time frame	Description
ovarian follicle count	24 hour	Ovarian reserve will be checked with ultrasound

Contacts

Primary Contactemine yılmaz güler

dr.emine.yilmaz@gmail.com905054525261

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026